Aurelien Zarca,Ilze Adlere,Cristina P Viciano,Marta Arimont-Segura,Max Meyrath,Icaro A Simon,Jan Paul Bebelman,Dennis Laan,Hans G J Custers,Elwin Janssen,Kobus L K Versteegh,Maurice Buzink,Desislava Nesheva,Reggie Bosma,Iwan J P de Esch,Henry Vischer,Maikel Wijtmans,Martyna Szpakowska,Andy Chevigné,Carsten Hoffmann,Chris de Graaf,Barbara A Zarzycka,Albert D Windhorst,Martine J Smit,Rob Leurs,Aurelien M. Zarca,Cristina P. Viciano,Icaro A. Simon,Hans G. J. Custers,Kobus L. Versteegh,Maurice C. M. L. Buzink,Desislava N. Nesheva,Iwan J. P. de Esch,Henry F. Vischer,Barbara A. Zarzycka,Albert D. Windhorst,Martine J. Smit

Abstract:Atypical chemokine receptor 3 (ACKR3), formerly referred to as CXCR7, is considered to be an interesting drug target. In this study, we report on the synthesis, pharmacological characterization and radiolabeling of VUF15485, a new ACKR3 small-molecule agonist, that will serve as an important new tool to study this β -arrestin-biased chemokine receptor. VUF15485 binds with nanomolar affinity (pIC 50 = 8.3) to human ACKR3, as measured in [ 125 I]CXCL12 competition binding experiments. Moreover, in a bioluminescence resonance energy transfer-based β -arrestin2 recruitment assay VUF15485 acts as a potent ACKR3 agonist (pEC 50 = 7.6) and shows a similar extent of receptor activation compared with CXCL12 when using a newly developed, fluorescence resonance energy transfer-based ACKR3 conformational sensor. Moreover, the ACKR3 agonist VUF15485, tested against a (atypical) chemokine receptor panel (agonist and antagonist mode), proves to be selective for ACKR3. VUF15485 labeled with tritium at one of its methoxy groups ([ 3 H]VUF15485), binds ACKR3 saturably and with high affinity ( K d = 8.2 nM). Additionally, [ 3 H]VUF15485 shows rapid binding kinetics and consequently a short residence time (<2 minutes) for binding to ACKR3. The selectivity of [ 3 H]VUF15485 for ACKR3, was confirmed by binding studies, whereupon CXCR3, CXCR4, and ACKR3 small-molecule ligands were competed for binding against the radiolabeled agonist. Interestingly, the chemokine ligands CXCL11 and CXCL12 are not able to displace the binding of [ 3 H]VUF15485 to ACKR3. The radiolabeled VUF15485 was subsequently used to evaluate its binding pocket. Site-directed mutagenesis and docking studies using a recently solved cryo-EM structure propose that VUF15485 binds in the major and the minor binding pocket of ACKR3. SIGNIFICANCE STATEMENT The atypical chemokine receptor atypical chemokine receptor 3 (ACKR3) is considered an interesting drug target in relation to cancer and multiple sclerosis. The study reports on new chemical biology tools for ACKR3, i.e., a new agonist that can also be radiolabeled and a new ACKR3 conformational sensor, that both can be used to directly study the interaction of ACKR3 ligands with the G protein-coupled receptor.

Labeling of CC Chemokine Receptor 2 with a Versatile Intracellular Allosteric Probe

N -Acyl- N -Alkyl Sulfonamide Probes for Ligand-Directed Covalent Labeling of GPCRs: The Adenosine A 2B Receptor as Case Study

A fluorescent probe enables the discovery of improved antagonists targeting the intracellular allosteric site of the chemokine receptor CCR7

Fluorophore-Labeled Pyrrolones Targeting the Intracellular Allosteric Binding Site of the Chemokine Receptor CCR1

Discovery of a Photoaffinity Probe that Captures the Active Conformation of the Cannabinoid CB2 Receptor

Structural And Biological Characterizations Of Novel High-Affinity Fluorescent Probes With Overlapped And Distinctive Binding Regions On Cxcr4

Platform Reagents Enable Synthesis of Ligand-Directed Covalent Probes: Study of Cannabinoid Receptor 2 in Live Cells

Identification of a novel allosteric binding site in the CXCR2 chemokine receptor

Visualization of membrane localization and functional state of CB2R pools by matched agonist and inverse agonist probe pairs

Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3

A chromatographic method for pursuing potential GPCR ligands with the capacity to characterize their intrinsic activities of regulating downstream signaling pathway

Multiplex Detection of Fluorescent Chemokine Binding to CXC Chemokine Receptors by NanoBRET

Chemically programmable bacterial probes for the recognition of cell surface proteins

ACKR3 Proximity Labeling Identifies Novel G protein- and β-arrestin-independent GPCR Interacting Proteins

A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening

Exploring an Intracellular Allosteric Site of CC-Chemokine Receptor 4 from 3D Models, Probe Simulations, and Mutagenesis

Label-Free Functional Assays of Chemical Receptors Using A Bioengineered Cell-Based Biosensor with Localized Extracellular Acidification Measurement

Strategies for positioning fluorescent probes and crosslinkers on formyl peptide ligands

Label-free optical biosensor for ligand-directed functional selectivity acting on beta(2) adrenoceptor in living cells

Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe